Can pharma prop up the digital health recession?

Can pharma prop up the digital health recession?

Even in a turbulent economy, investors and buyers claim that pharma-related innovations are piqueing their interest. Pharmaceutical corporations are prepared to invest in clinical trial technologies and digital therapies even though the digital health ecosystem anticipates a significant reset in 2023. Additionally, payers and retail businesses like CVS and Walgreens are interested in pharma-related technologies. According to experts, all of this could create a significant opportunity for both investors and businesses involved in digital health. According to Dr. Sunny Kumar, a partner at the venture capital firm GSR Ventures, "One market that is still keen to spend is pharma, particularly on the clinical trials sector." The Digital Health Business & Technology database shows that businesses that specialise in digital health trial technology have raised close to $165 million this year across nine agreements.

Related Offerings

Next Article

Did you find this useful?

Medigy Innovation Network

Connecting innovation decision makers to authoritative information, institutions, people and insights.

Medigy Logo

The latest News, Insights & Events

Medigy accurately delivers healthcare and technology information, news and insight from around the world.

The best products, services & solutions

Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.

© 2023 Netspective Media LLC. All Rights Reserved.

Built on Jan 27, 2023 at 2:25pm